- Home
- ATXI vs SPRC Comparison
ATXI vs SPRC Comparison
Compare ATXI & SPRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXI
- SPRC
- Stock Information
- Founded
- ATXI 2015
- SPRC 2004
- Country
- ATXI United States
- SPRC Israel
- Employees
- ATXI N/A
- SPRC N/A
- Industry
- ATXI Biotechnology: Pharmaceutical Preparations
- SPRC Biotechnology: Pharmaceutical Preparations
- Sector
- ATXI Health Care
- SPRC Health Care
- Exchange
- ATXI Nasdaq
- SPRC Nasdaq
- Market Cap
- ATXI 3.0M
- SPRC 2.5M
- IPO Year
- ATXI 2017
- SPRC N/A
- Fundamental
- Price
- ATXI $1.85
- SPRC $0.22
- Analyst Decision
- ATXI
- SPRC
- Analyst Count
- ATXI 0
- SPRC 0
- Target Price
- ATXI N/A
- SPRC N/A
- AVG Volume (30 Days)
- ATXI 22.1K
- SPRC 668.4K
- Earning Date
- ATXI 11-14-2024
- SPRC 02-15-2025
- Dividend Yield
- ATXI N/A
- SPRC N/A
- EPS Growth
- ATXI N/A
- SPRC N/A
- EPS
- ATXI N/A
- SPRC N/A
- Revenue
- ATXI N/A
- SPRC $1,747,000.00
- Revenue This Year
- ATXI N/A
- SPRC N/A
- Revenue Next Year
- ATXI N/A
- SPRC N/A
- P/E Ratio
- ATXI N/A
- SPRC N/A
- Revenue Growth
- ATXI N/A
- SPRC N/A
- 52 Week Low
- ATXI $1.60
- SPRC $0.21
- 52 Week High
- ATXI $26.48
- SPRC $6.78
- Technical
- Relative Strength Index (RSI)
- ATXI 30.21
- SPRC 43.97
- Support Level
- ATXI $1.80
- SPRC $0.24
- Resistance Level
- ATXI $1.88
- SPRC $0.29
- Average True Range (ATR)
- ATXI 0.11
- SPRC 0.02
- MACD
- ATXI -0.02
- SPRC -0.00
- Stochastic Oscillator
- ATXI 0.00
- SPRC 9.73
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
About SPRC SciSparc Ltd.
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.